183 related articles for article (PubMed ID: 30076277)
1. NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Gregorc V; Cavina R; Novello S; Grossi F; Lazzari C; Capelletto E; Genova C; Salini G; Lambiase A; Santoro A
Oncologist; 2018 Oct; 23(10):1133-e112. PubMed ID: 30076277
[TBL] [Abstract][Full Text] [Related]
2. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V; Santoro A; Bennicelli E; Punt CJ; Citterio G; Timmer-Bonte JN; Caligaris Cappio F; Lambiase A; Bordignon C; van Herpen CM
Br J Cancer; 2009 Jul; 101(2):219-24. PubMed ID: 19568235
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702.
Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T
Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.
Lorusso D; Scambia G; Amadio G; di Legge A; Pietragalla A; De Vincenzo R; Masciullo V; Di Stefano M; Mangili G; Citterio G; Mantori M; Lambiase A; Bordignon C
Br J Cancer; 2012 Jun; 107(1):37-42. PubMed ID: 22644293
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
Gregorc V; Zucali PA; Santoro A; Ceresoli GL; Citterio G; De Pas TM; Zilembo N; De Vincenzo F; Simonelli M; Rossoni G; Spreafico A; Grazia Viganò M; Fontana F; De Braud FG; Bajetta E; Caligaris-Cappio F; Bruzzi P; Lambiase A; Bordignon C
J Clin Oncol; 2010 May; 28(15):2604-11. PubMed ID: 20406925
[TBL] [Abstract][Full Text] [Related]
7. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Mammoliti S; Andretta V; Bennicelli E; Caprioni F; Comandini D; Fornarini G; Guglielmi A; Pessino A; Sciallero S; Sobrero AF; Mazzola G; Lambiase A; Bordignon C
Ann Oncol; 2011 Apr; 22(4):973-978. PubMed ID: 20855468
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
[TBL] [Abstract][Full Text] [Related]
9. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma.
Ferreri AJM; Calimeri T; Conte GM; Cattaneo D; Fallanca F; Ponzoni M; Scarano E; Curnis F; Nonis A; Lopedote P; Citterio G; Politi LS; Foppoli M; Girlanda S; Sassone M; Perrone S; Cecchetti C; Ciceri F; Bordignon C; Corti A; Anzalone N
Blood; 2019 Jul; 134(3):252-262. PubMed ID: 31118164
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW; Fiedler W; Desar IM; van Asten JJ; Marréaud S; Lacombe D; Govaerts AS; Bogaerts J; Lasch P; Timmer-Bonte JN; Lambiase A; Bordignon C; Punt CJ; Heerschap A; van Herpen CM
Clin Cancer Res; 2010 Feb; 16(4):1315-23. PubMed ID: 20145168
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.
Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
[TBL] [Abstract][Full Text] [Related]
15. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Naito Y; Yamada K; Imamura Y; Ishii H; Matsuo N; Tokito T; Kinoshita T; Azuma K; Hoshino T
Med Oncol; 2018 Apr; 35(5):61. PubMed ID: 29610997
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
Samantas E; Kalofonos H; Linardou H; Nicolaides C; Mylonakis N; Fountzilas G; Kosmidis P; Skarlos D
Ann Oncol; 2000 Nov; 11(11):1395-7. PubMed ID: 11142478
[TBL] [Abstract][Full Text] [Related]
17. Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.
Ferreri AJM; Calimeri T; Ponzoni M; Curnis F; Conte GM; Scarano E; Rrapaj E; De Lorenzo D; Cattaneo D; Fallanca F; Nonis A; Foppoli M; Lopedote P; Citterio G; Politi LS; Sassone M; Angelillo P; Guggiari E; Steffanoni S; Tarantino V; Ciceri F; Bordignon C; Anzalone N; Corti A
Blood Adv; 2020 Aug; 4(15):3648-3658. PubMed ID: 32766857
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
19. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
[TBL] [Abstract][Full Text] [Related]
20. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A; Pressiani T; Citterio G; Rossoni G; Donadoni G; Pozzi F; Rimassa L; Personeni N; Bozzarelli S; Rossoni G; Colombi S; De Braud FG; Caligaris-Cappio F; Lambiase A; Bordignon C
Br J Cancer; 2010 Sep; 103(6):837-44. PubMed ID: 20717115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
